Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus NORETHINDRONE AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus NORETHINDRONE AND ETHINYL ESTRADIOL.
AMEN vs NORETHINDRONE AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation. Thickens cervical mucus to inhibit sperm penetration. Alters endometrium to reduce implantation likelihood.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
One tablet (norethindrone 1 mg / ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo or no tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Norethindrone: 6-8 hours (terminal); Ethinyl estradiol: 13-27 hours (terminal, mean ~17 hours). Half-life supports once-daily dosing for contraceptive efficacy.
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Norethindrone: ~50% renal (as metabolites), ~50% fecal (biliary). Ethinyl estradiol: ~40% renal, ~60% fecal (primarily as glucuronide conjugates).
Category C
Category D/X
Progestin
Progestin